December 19: The Week in Cancer News
Proton therapy for oropharyngeal cancer increases overall survival, and risk-based screening for breast cancer appears to be as effective as annual screening.
Progress Against Cancer
Proton therapy for oropharyngeal cancer increases overall survival, and risk-based screening for breast cancer appears to be as effective as annual screening.
A year-end review of some of the new cancer treatments, exciting breakthroughs, and insights into cancer's development that emerged in 2025.
Patients now have the option of receiving the bispecific antibody amivantamab as an injection. The U.S. Food and Drug Administration (FDA) has approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) for subcutaneous injection as an alternative...
The FDA has converted the accelerated approval of rucaparib to full approval for certain patients with metastatic castration-resistant prostate cancer. The U.S. Food and Drug Administration (FDA) has granted traditional approval to rucaparib (Rubraca)...
Fam-trastuzumab deruxtecan-nxki (T-DXd) with pertuzumab was approved to treat metastatic HER2-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for patients with...
Clinical trial presented at SABCS finds some patients may safely skip sentinel lymph node biopsy.
In clinical trials presented at SABCS, a mobile health tool and acupuncture helped to improve breast cancer survivors' quality of life.
The FDA approved a combination of the PARP inhibitor niraparib with a hormone therapy agent plus a corticosteroid for certain patients with metastatic prostate cancer. The U.S. Food and Drug Administration (FDA) has approved...
The addition of targeted therapy helps control metastatic breast cancer, and a pair of immunotherapy drugs prolongs survival in multiple myeloma.
Amid the debate over menopausal hormone therapy and cancer risk, researchers at SABCS provided some clarity for women with BRCA1/2 mutations.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More